Ionis Pharmaceuticals, Inc. IONS

The latest trades reveal where Wood sees opportunity

Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight. With the share price under pressure, the real issue for investors is how well the current valuation lines up with the sales its business is generating and may be able to support over time. The stock is down about 45.0% year to date. This puts a sharp spotlight on whether today's market value still lines up with what Ionis can justify through its sales...

Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN). "These interim phase 3 results show the clinical potential of sefaxersen to modify a key surrogate endpoint of kidney function in people with IgA nephropathy’’ said Levi Garraway, Roche’s Chief Medical Officer and Head of Glo

CARLSBAD, Calif., September 23, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine prote

CARLSBAD, Calif., September 22, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with amyotrophic lateral sclerosis (ALS) caused by mutations in the fused in sarcoma (FUS) gene, also known as FUS-ALS. The study met its primary endpoint, with ulefnersen demonstrating a statistically

ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.

Ark Invest added nearly $25 million of CoreWeave as it trimmed several major AI and technology holdings

Ionis Pharmaceuticals (IONS) is back in focus after partner Novartis reported that the pivotal Phase 3 Lp(a)HORIZON trial of pelacarsen failed to reduce major cardiovascular events despite sharply lowering Lp(a) levels. The pelacarsen setback comes after a sharp reset in sentiment. Ionis Pharmaceuticals has posted a 7-day share price return of negative 15.99% and a 30-day share price return of negative 21.59%. Despite this, the company still has a 5-year total shareholder return of 25.67%,...